Juha Onatsu1, Mikko Taina2, Pirjo Mustonen3, Marja Hedman2, Antti Muuronen2, Otso Arponen2, Miika Korhonen2, Pekka Jäkälä4,5, Ritva Vanninen2,6, Kari Pulkki7,8. 1. Department of Neurology, NeuroCenter, Kuopio University Hospital, Kuopio, Finland Juha.Onatsu@kuh.fi. 2. Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland. 3. Department of Cardiology, Keski-Suomi Central Hospital, Jyväskylä, Finland. 4. Department of Neurology, NeuroCenter, Kuopio University Hospital, Kuopio, Finland. 5. Unit of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland. 6. Department of Clinical Radiology, University of Eastern Finland, Kuopio, Finland. 7. Department of Clinical Chemistry, University of Eastern Finland, Kuopio, Finland. 8. Eastern Finland Laboratory Centre, Kuopio, Finland.
Abstract
AIM: We evaluated soluble urokinase-type plasminogen activator receptor (suPAR) levels in different stroke subtypes and assessed their prognostic value regarding 5-year outcomes. MATERIALS AND METHODS: The study included 117 stroke patients (81 males; mean=age 61±11 years) with suspected cardioembolic stroke whose plasma suPAR concentration was assessed. Altogether, 20 (17.1%) patients suffered from stroke as a result of cardioembolism, 12 (10.3%) from large-artery atherosclerosis, 9 (7.7%) from small-vessel disease, 11 (9.4%) from both large-artery and cardioembolic etiology, and 65 (55.6%) had cryptogenic stroke. The mean follow-up period was 5 years. RESULTS: suPAR concentration was higher in patients who suffered from stroke/transient ischemic attack due to large-artery atherosclerosis (3.2±0.9 ng/ml) compared to small-vessel disease (2.0±0.5 ng/ml, p<0.001). An elevated plasma suPAR concentration was associated with all-cause mortality during the follow-up period (p=0.003). CONCLUSION: Elevated plasma suPAR concentrations predicted all-cause mortality during the 5-year follow-up after ischemic stroke. suPAR was not able to differentiate patients with cardioembolic stroke from those with other stroke types. Copyright
AIM: We evaluated soluble urokinase-type plasminogen activator receptor (suPAR) levels in different stroke subtypes and assessed their prognostic value regarding 5-year outcomes. MATERIALS AND METHODS: The study included 117 strokepatients (81 males; mean=age 61±11 years) with suspected cardioembolic stroke whose plasma suPAR concentration was assessed. Altogether, 20 (17.1%) patients suffered from stroke as a result of cardioembolism, 12 (10.3%) from large-artery atherosclerosis, 9 (7.7%) from small-vessel disease, 11 (9.4%) from both large-artery and cardioembolic etiology, and 65 (55.6%) had cryptogenic stroke. The mean follow-up period was 5 years. RESULTS:suPAR concentration was higher in patients who suffered from stroke/transient ischemic attack due to large-artery atherosclerosis (3.2±0.9 ng/ml) compared to small-vessel disease (2.0±0.5 ng/ml, p<0.001). An elevated plasma suPAR concentration was associated with all-cause mortality during the follow-up period (p=0.003). CONCLUSION: Elevated plasma suPAR concentrations predicted all-cause mortality during the 5-year follow-up after ischemic stroke. suPAR was not able to differentiate patients with cardioembolic stroke from those with other stroke types. Copyright
Authors: Petri Sipola; Marja Hedman; Juha Onatsu; Anu Turpeinen; Matti Halinen; Pekka Jäkälä; Ritva Vanninen Journal: Cerebrovasc Dis Date: 2013-06-25 Impact factor: 2.762
Authors: Robert G Hart; Hans-Christoph Diener; Shelagh B Coutts; J Donald Easton; Christopher B Granger; Martin J O'Donnell; Ralph L Sacco; Stuart J Connolly Journal: Lancet Neurol Date: 2014-04 Impact factor: 44.182
Authors: Antti T Muuronen; Mikko Taina; Marja Hedman; Jarkko Marttila; Johanna Kuusisto; Juha Onatsu; Ritva Vanninen; Pekka Jäkälä; Petri Sipola; Pirjo Mustonen Journal: PLoS One Date: 2015-03-10 Impact factor: 3.240
Authors: Waldemar Gozdzik; Barbara Adamik; Anna Gozdzik; Maciej Rachwalik; Wojciech Kustrzycki; Andrzej Kübler Journal: PLoS One Date: 2014-06-09 Impact factor: 3.240
Authors: Juha Onatsu; Ritva Vanninen; Pekka JÄkÄlÄ; Pirjo Mustonen; Kari Pulkki; Miika Korhonen; Marja Hedman; Kina HÖglund; Kaj Blennow; Henrik Zetterberg; Sanna-Kaisa Herukka; Mikko Taina Journal: In Vivo Date: 2020 Sep-Oct Impact factor: 2.155
Authors: Tobias P Schmidt; Walid Albanna; Miriam Weiss; Michael Veldeman; Catharina Conzen; Omid Nikoubashman; Christian Blume; Daniel S Kluger; Hans Clusmann; Sven H Loosen; Gerrit A Schubert Journal: Front Neurol Date: 2022-03-10 Impact factor: 4.003